Skip to main content

Table 1 Demographic and clinical characteristics of subjects included in the study 1 and 2 a

From: Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls

 

Control

AD

Study 1 (paired plasma + CSF)

n = 20

n = 25

 Sex, n, female/male  (% female)

12/8 (60)

14/11 (56)

 Age at LP, yr

54 (41 to 63)

76 (71 to 78)b

 CSF Aβ1–42, pg/ml

1,399 (1189 to 1702)

709 (588 to 897)b

 CSF Aβ1–42 /1–40 ratio

0.094 (0.079 to 0.104)

0.033 (0.028 to 0.042)b

 CSF t-tau, pg/ml

185 (136 to 254)

580 (425 to 655)b

 CSF p-tau, pg/ml

35 (27 to 45)

89 (78 to 105 to 126)b

 CSF Ng, pg/ml (MSD)

291 (251 to 438)

620 (521 to 818)b

 Plasma Ng, pg/ml (MSD)

47,451 (21,904 to 90,320)

36,525 (25,324 to 57,715)

 Plasma, pg/ml (HI-MS)

21,698 (13,401 to 106,954)

25,644 (17,262 to 53,900)

Study 2 (plasma)

n = 17

n = 13

 Sex, n, female/male  (% female)

9/17 (53)

9/13 (69)

 Age at LP, yr

58 (53 to 68)

78 (69 to 80)b

 CSF Aβ1–42, pg/ml

875 (580 to 940)

330 (268 to 415)b

 CSF t-tau, pg/ml

300 (210 to 348)

690 (605 to 980)b

 CSF p-tau, pg/ml

48 (40 to 61)

110 (77 to 160)b

  1. aAβ, Amyloid-β; AD, Alzheimer’s disease; CSF, Cerebrospinal fluid; HI-MS, Hybrid immunoaffinity-mass spectrometry; LP, lumbar puncture; MSD, Meso Scale Discovery; Ng, Neurogranin; p-tau, Phosphorylated tau; t-tau, Total tau. The values presented are median (interquartile range). b P < 0.001 vs. controls.